Trial Profile
A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2014
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 12 Jul 2012 New trial record